THE EFFECTS OF 3 BIOREDUCTIVE DRUGS (MITOMYCIN-C, RSU-1069 AND SR4233) ON CELL-LINES SELECTED FOR THEIR SENSITIVITY TO MITOMYCIN-C OR IONIZING-RADIATION

被引:21
作者
KEOHANE, A
GODDEN, J
STRATFORD, IJ
ADAMS, GE
机构
[1] MRC Radiobiology Unit, Chilton, Didcot, Oxon
基金
英国医学研究理事会;
关键词
D O I
10.1038/bjc.1990.162
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated the cross-sensitivity of a number of cell lines to three different classes of bioreductive drugs under both aerobic and hypoxic conditions. The cell lines used were selected for their sensitivity to DNA-damaging agents and fall into two groups. One group, MMC cells derived from CHO-K1 cells (Robson et al., 1985), show a range of sensitivities to mitomycin C in air. The second group, irs cells were cloned from V79 Chinese hamster fibroblasts (Jones et al., 1987) and exhibit sensitivity to ionising radiation. The sensitivity of both groups of cells to mitomycin C (MMC), RSU-1069 and SR4233 was assessed under aerobic and hypoxic conditions. No difference in aerobic or hypoxic toxicity of MMC was observed for CHO-K1 or MMC sensitive cell lines (MMC-2 and MMC-3). However, the MMC-resistant cell line (MMC) was 10 times more sensitive under hypoxic than aerobic conditions. This suggests that MMC cells lack or are deficient in the enzymes responsible for activating MMC under aerobic conditions compared to other MMC cells. In contrast, differential toxicities of between 3 and 30 have been observed for all CHO cells treated with RSU-1069 and SR4233. Treatment of V79 and irs cells with RSU-1069 and SR4233 also resulted in selective toxicity towards hypoxic cells. Differential toxicities between 50 and 100 were observed for V79 cells. For both RSU-1069 and SR4233, the hypoxic toxicities were similar in V79 and irs cells but in air, the radiation sensitive cells were up to 10 times more sensitive than wild type cells. © The MacMillan Press Ltd., 1990.
引用
收藏
页码:722 / 726
页数:5
相关论文
共 17 条
  • [1] RSU-1069, A 2-NITROIMIDAZOLE CONTAINING AN ALKYLATING GROUP - HIGH-EFFICIENCY AS A RADIOSENSITIZER AND CHEMOSENSITIZER INVITRO AND INVIVO
    ADAMS, GE
    AHMED, I
    SHELDON, PW
    STRATFORD, IJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (09): : 1653 - 1656
  • [2] DULHANTY AM, 1989, CANCER RES, V49, P117
  • [3] HOBAN DJ, 1990, IN PRESS CANCER RES
  • [4] ISOLATION AND CROSS-SENSITIVITY OF X-RAY-SENSITIVE MUTANTS OF V79-4 HAMSTER-CELLS
    JONES, NJ
    COX, R
    THACKER, J
    [J]. MUTATION RESEARCH, 1987, 183 (03): : 279 - 286
  • [5] HYPOXIC TUMOR-CELL - TARGET FOR SELECTIVE CANCER-CHEMOTHERAPY
    KENNEDY, KA
    TEICHER, BA
    ROCKWELL, S
    SARTORELLI, AC
    [J]. BIOCHEMICAL PHARMACOLOGY, 1980, 29 (01) : 1 - 8
  • [6] KEYES SR, 1984, CANCER RES, V44, P5638
  • [7] THE DEVELOPMENT OF HYPOXIC TUMOR-CELL CYTO-TOXIC AGENTS
    KIRKPATRICK, DL
    [J]. PHARMACOLOGY & THERAPEUTICS, 1989, 40 (03) : 383 - 399
  • [8] DEFICIENT ACTIVATION BY A HUMAN CELL STRAIN LEADS TO MITOMYCIN RESISTANCE UNDER AEROBIC BUT NOT HYPOXIC CONDITIONS
    MARSHALL, RS
    PATERSON, MC
    RAUTH, AM
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (03) : 341 - 346
  • [9] ROLE OF CATALYTIC SUPEROXIDE FORMATION IN O2 INHIBITION OF NITROREDUCTASE
    MASON, RP
    HOLTZMAN, JL
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1975, 67 (04) : 1267 - 1274
  • [10] ROBSON CN, 1985, CANCER RES, V45, P5304